As of November 8, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Unicycive Therapeutics, Inc. The largest reported stake is Bvf Partners L P's, at 9.99%. 18 filings are on record since August 12, 2025 (Schedule 13G/A, August 14, 2025).
Sell to companies like Unicycive Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Nantahala Capital Management, LLC · Sole voting: 0 · Shared voting: 2,807,830 · Sole dispositive: 0 · Shared dispositive: 2,807,830 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Vivo Opportunity Fund Holdings, L.P. · Sole voting: 4,856,259 · Shared voting: 0 · Sole dispositive: 4,856,259 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: BlackRock, Inc. · Sole voting: 1,391,049 · Shared voting: 0 · Sole dispositive: 1,413,381 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-30
- · Reporting person: Integrated Core Strategies (US) LLC · Sole voting: 0 · Shared voting: 205,529 · Sole dispositive: 0 · Shared dispositive: 205,529 · SCHEDULE 13G/A, 2026-07-08
- · Holder: RA Capital Management, L.P. · Percent: 9.9% · SCHEDULE 13G/A
Unicycive Therapeutics, Inc. has 18 Schedule 13D or 13G filings on record since 2025-08-12. 5 holders' latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Bvf Partners L P | 9.99% | 1,417,117 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Nantahala Capital Management, LLC | 9.99% | 2,807,830 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Vivo Opportunity Fund Holdings, L.P. | 9.99% | 4,856,259 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| RA Capital Management, L.P. | 9.9% | 2,801,082 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| BlackRock, Inc. | 5.3% | 1,413,381 | SCHEDULE 13G, 2026-07-30 | 2026-06-30 |
| Octagon Capital Advisors LP | 4.7% | 1,000,000 | SCHEDULE 13G/A, 2026-02-10 | 2025-12-31 |
| Great Point Partners, LLC | 4.51% | 796,558 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Millennium Management LLC | 1% | 271,456 | SCHEDULE 13G/A, 2026-07-08 | 2026-06-30 |
Holding shares or following this stake? See who's behind Unicycive Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Unicycive Therapeutics, Inc. and the records around it.
Unicycive Therapeutics, Inc. elsewhere on the record
- Leadership changes Apr 2026
- Who owns it
Companies that share a holder
- Octagon Capital Advisors LP also filed stake reports on 8 other companies: Precision BioSciences, Inc. (Nov 2026), Context Therapeutics Inc. (Jul 2026), Corbus Pharmaceuticals Holdings, Inc. (May 2026)
- Great Point Partners, LLC also filed stake reports on 14 other companies: LeonaBio, Inc. (Nov 2026), Research Alliance Corporation III (Sep 2026), JATT III Acquisition Corp (Sep 2026)
- Vivo Opportunity Fund Holdings, L.P. also filed stake reports on 20 other companies: ArriVent BioPharma, Inc. (Oct 2026), Clene Inc. (Aug 2026), Compass Therapeutics, Inc. (Aug 2026)
Watch Unicycive Therapeutics, Inc.
Get an email when Unicycive Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Unicycive Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Unicycive Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Unicycive Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 0 | 2,807,830 | 0 | 2,807,830 | SCHEDULE 13G/A, 2026-08-14 |
| Wilmot B. Harkey | 0 | 2,807,830 | 0 | 2,807,830 | SCHEDULE 13G/A, 2026-08-14 |
| Daniel Mack | 0 | 2,807,830 | 0 | 2,807,830 | SCHEDULE 13G/A, 2026-08-14 |
| Vivo Opportunity Fund Holdings, L.P. | 4,856,259 | 0 | 4,856,259 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Vivo Opportunity, LLC | 4,856,259 | 0 | 4,856,259 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| BlackRock, Inc. | 1,391,049 | 0 | 1,413,381 | 0 | SCHEDULE 13G, 2026-07-30 |
| Integrated Core Strategies (US) LLC | 0 | 205,529 | 0 | 205,529 | SCHEDULE 13G/A, 2026-07-08 |
| Millennium Management LLC | 0 | 271,456 | 0 | 271,456 | SCHEDULE 13G/A, 2026-07-08 |
| Millennium Group Management LLC | 0 | 271,456 | 0 | 271,456 | SCHEDULE 13G/A, 2026-07-08 |
| Israel A. Englander | 0 | 271,456 | 0 | 271,456 | SCHEDULE 13G/A, 2026-07-08 |
The latest filing identifies Unicycive Therapeutics, Inc. by CUSIP 90466Y202 and gives its principal executive office as 1975 W. EL CAMINO REAL, SUITE 204, MOUNTAIN VIEW, CA 94040 (SCHEDULE 13G/A, 2026-08-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-12 | Octagon Capital Advisors LP | 7.8% | SCHEDULE 13G/A |
| 2025-08-14 | Bvf Partners L P | 9.99% | SCHEDULE 13G/A |
| 2025-08-14 | Nantahala Capital Management, LLC | 9.99% | SCHEDULE 13G/A |
| 2025-08-14 | Great Point Partners, LLC | 6.24% | SCHEDULE 13G/A |
| 2025-11-14 | Nantahala Capital Management, LLC | 9.99% | SCHEDULE 13G/A |
| 2025-11-14 | Vivo Opportunity Fund Holdings, L.P. | 9.99% | SCHEDULE 13G/A |
| 2025-11-14 | Octagon Capital Advisors LP | 5.7% | SCHEDULE 13G/A |
| 2025-11-14 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G/A |
| 2025-11-14 | Great Point Partners, LLC | 4.51% | SCHEDULE 13G/A |
| 2026-01-23 | Integrated Core Strategies (US) LLC | 5.5% | SCHEDULE 13G |
| 2026-02-10 | Octagon Capital Advisors LP | 4.7% | SCHEDULE 13G/A |
| 2026-02-13 | Nantahala Capital Management, LLC | 9.99% | SCHEDULE 13G/A |
| 2026-02-17 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G/A |
| 2026-05-15 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G/A |
| 2026-07-08 | Millennium Management LLC | 1% | SCHEDULE 13G/A |
| 2026-07-30 | BlackRock, Inc. | 5.3% | SCHEDULE 13G |
| 2026-08-14 | Nantahala Capital Management, LLC | 9.99% | SCHEDULE 13G/A |
| 2026-08-14 | Vivo Opportunity Fund Holdings, L.P. | 9.99% | SCHEDULE 13G/A |
Questions about who owns Unicycive Therapeutics, Inc.
Who owns Unicycive Therapeutics, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Unicycive Therapeutics, Inc.: Bvf Partners L P (9.99%, Schedule 13G/A, filed 2025-08-14), Nantahala Capital Management, LLC (9.99%, Schedule 13G/A, filed 2026-08-14), Vivo Opportunity Fund Holdings, L.P. (9.99%, Schedule 13G/A, filed 2026-08-14), RA Capital Management, L.P. (9.9%, Schedule 13G/A, filed 2026-05-15) and BlackRock, Inc. (5.3%, Schedule 13G, filed 2026-07-30).
Who are the largest shareholders of Unicycive Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Unicycive Therapeutics, Inc. on this page are Bvf Partners L P (9.99%), Nantahala Capital Management, LLC (9.99%) and Vivo Opportunity Fund Holdings, L.P. (9.99%).
When did Bvf Partners L P buy into Unicycive Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Bvf Partners L P on this page is the Schedule 13G/A, filed 2025-08-14, reporting 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 18 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Unicycive Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 29, 2026 | Leadership change: Meredith S. Manning appointed, Director | — | Leadership changes | Source |
| April 6, 2026 | Leadership change: Gaurav Aggarwal departs, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Unicycive Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.